# Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

> **NCT00647764** · PHASE1 · COMPLETED · sponsor: **Esanex Inc.** · enrollment: 32 (actual)

## Conditions studied

- Solid Tumor Malignancy
- Lymphoid Malignancy (Lymphoma and CLL)
- Leukemia
- Lymphoma

## Interventions

- **DRUG:** SNX-5422 Mesylate Hsp90 inhibitor

## Key facts

- **NCT ID:** NCT00647764
- **Lead sponsor:** Esanex Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2012-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00647764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00647764, "Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00647764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*